Insights into Uromodulin and Blood Pressure

IF 3.9 2区医学 Q1 PERIPHERAL VASCULAR DISEASE Current Hypertension Reports Pub Date : 2024-09-11 DOI:10.1007/s11906-024-01317-0

Manshi Zhou, Sheon Mary, Christian Delles, Sandosh Padmanabhan, Delyth Graham, Martin W. McBride, Anna F. Dominiczak

{"title":"Insights into Uromodulin and Blood Pressure","authors":"Manshi Zhou, Sheon Mary, Christian Delles, Sandosh Padmanabhan, Delyth Graham, Martin W. McBride, Anna F. Dominiczak","doi":"10.1007/s11906-024-01317-0","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose of Review</h3><p>We review the role of uromodulin, a protein exclusively expressed in the kidney, in blood pressure regulation and hypertension.</p><h3 data-test=\"abstract-sub-heading\">Recent Findings</h3><p>The last few years have seen a shift of focus from genetic association to mendelian randomisation and uromodulin-salt interaction studies, thus confirming the causal role of uromodulin in blood pressure regulation and hypertension. This work has been complemented by phenome-wide association studies in a wider range of ethnicities. Important recent molecular work elucidated uromodulin trafficking and secretion and provided more insights into the pathophysiological roles of circulating and urinary uromodulin.</p><h3 data-test=\"abstract-sub-heading\">Summary</h3><p>Uromodulin has a causal role in blood pressure regulation and hypertensin. Recent studies show utility of the uromodulin as a biomarker and a possible precision medicine application based on genetically determined differential responses to loop diuretics.</p>","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":"8 1","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hypertension Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11906-024-01317-0","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of Review

We review the role of uromodulin, a protein exclusively expressed in the kidney, in blood pressure regulation and hypertension.

Recent Findings

The last few years have seen a shift of focus from genetic association to mendelian randomisation and uromodulin-salt interaction studies, thus confirming the causal role of uromodulin in blood pressure regulation and hypertension. This work has been complemented by phenome-wide association studies in a wider range of ethnicities. Important recent molecular work elucidated uromodulin trafficking and secretion and provided more insights into the pathophysiological roles of circulating and urinary uromodulin.

Summary

Uromodulin has a causal role in blood pressure regulation and hypertensin. Recent studies show utility of the uromodulin as a biomarker and a possible precision medicine application based on genetically determined differential responses to loop diuretics.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

对尿嘧啶和血压的深入了解

综述目的我们综述了尿调节蛋白（一种只在肾脏中表达的蛋白质）在血压调节和高血压中的作用。最近的研究结果在过去几年中，研究重点从遗传关联转向了泯灭随机化和尿调节蛋白-盐相互作用研究，从而证实了尿调节蛋白在血压调节和高血压中的因果作用。在更广泛的种族范围内开展的全表型关联研究对这项工作进行了补充。最近的重要分子研究阐明了尿调节蛋白的运输和分泌，并对循环和尿中尿调节蛋白的病理生理作用提供了更多的见解。最近的研究表明，尿调节蛋白可作为一种生物标志物，并可根据基因决定的对环利尿剂的不同反应应用于精准医疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Hypertension Reports 医学-外周血管病

CiteScore

10.50

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hypertension. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as antihypertensive therapies, associated metabolic disorders, and therapeutic trials. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.